Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB:PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU) for the development and commercialization of the IP of ketamine for the treatment of the Rett Syndrome (RTS), a rare genetic neurological disorder that causes severe muscle movement disability.
Current FDA-approved drugs do not offer any cure for Rett syndrome. This rare disorder occurs almost exclusively in girls and leads to severe impairments in their ability to speak, walk, eat and even breathe.
